E. A. Espiner, M.D., M.R.A.C.P., P. I. Jagger, M.D., J. R. Tucci, M.D., and D. P. Lauler, M.D. In nine separate studies on four patients with severe pitting edema ...

A new study published in the journal of Anesthesiology Research and Practice showed that the cardioprotective advantages of ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

A highly selective aldosterone synthase inhibitor, lorundrostat, showed promise for blood pressure reduction in a double-blind randomized phase IIb trial. Participants with uncontrolled and otherwise ...

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat, an aldosterone synthase inhibitor, significantly decreased automated office systolic BP ...

Current treatment options for primary aldosteronism are limited to surgery or mineralocorticoid receptor antagonists when surgery isn't an option. In a phase IIa trial, baxdrostat resolved or reduced ...

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat safely lowered 24-hour systolic BP compared with placebo in a phase 2 trial. A ...